A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia: CALGB 100801 (Alliance)
- Citation:
- Biol Blood Marrow Transplant vol 25 (10) 1984-92
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Program:
- OGC
- Primary Committee:
- Transplant
- Sec. Committees:
- Pharmas:
- Otsuka
- Grants:
- U10CA180821, U10CA180882, U10CA180833, U10CA180838, U10CA180850, U10CA180854, UG1CA189819
- Corr. Author:
- Authors:
- Ravi Vij Jennifer Le-Rademacher Kristina Laumann Vera Hars Kouros Owzar Tsiporah Shore Sumithira Vasu Amanda Cashen Luis Isola Thomas Shea Margarida DeMagalhaes-Silverman David Hurd Kenneth Meehan Frank Beardell Steven Devine
- Networks:
- CHRISTIANA, LAPS-MO011, LAPS-NC007, LAPS-NH012, LAPS-OH007, NC002, NY018, NY021
- Study
- CALGB-100801
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: